• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Senti Biosciences, Inc.

Senti Bio Announces Reverse Stock Split
July 16, 2024
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
July 01, 2024
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
May 13, 2024
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
May 09, 2024
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
April 30, 2024
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
March 21, 2024
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
January 05, 2024
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
December 22, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
November 13, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
November 06, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
October 31, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
September 27, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio to Participate in Upcoming Conferences
September 26, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio to Participate in Upcoming Investor Conferences
September 05, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
August 11, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
August 10, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 20, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces First Quarter 2023 Results and Pipeline Updates
May 09, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting
May 02, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting
April 17, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio to Participate in Upcoming Investor Conferences
April 14, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Biosciences Announces New Employment Inducement Grants
February 03, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio to Present at the SVB Securities Global Biopharma Conference
February 01, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
January 27, 2023
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
December 19, 2022
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event
December 11, 2022
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting
November 23, 2022
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Reports Third Quarter Financial Results and Pipeline Updates
November 10, 2022
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting
November 03, 2022
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Senti Bio Announces New Employment Inducement Grants
October 28, 2022
From Senti Biosciences, Inc.
Via GlobeNewswire
Tickers SNTI
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap